Anticancer research最新文献

{"title":"Blocking CXCR3B Expression Increases Tumor Aggressiveness in Hepatocellular Carcinoma.","authors":"Hwan Hee Lee, Seoyeon Oh, Hyojeung Kang, Hyosun Cho","doi":"10.21873/anticanres.17357","DOIUrl":"https://doi.org/10.21873/anticanres.17357","url":null,"abstract":"<p><strong>Background/aim: </strong>CXCR3B has been positively involved in the inhibition of cancer and angiogenesis. The present study investigated the role of CXCR3B in a cell model of hepatocellular carcinoma, SK-Hep1.</p><p><strong>Materials and methods: </strong>The blockade of CXCR3B expression in SK-Hep1 was investigated in terms of cell viability, cell cycle, and cell apoptosis using MTT assay and flow cytometry. In addition, the effect of blocking CXCR3B expression on cell migration and invasion was examined using scratch motility, transwell migration, and invasion assays. Furthermore, the cytotoxic effect of NK-92 cells against CXCR3B blocked SK-Hep1 was analyzed using the CytoTox96 assay, and the expression of NKp30⁺, NKG2D⁺, and NKG2C⁺ on NK-92 cells in a co-culture with SK-Hep1 was measured using flow cytometry.</p><p><strong>Results: </strong>Blocking CXCR3B expression had no effect on the viability, cell cycle or apoptosis of SK-Hep1 cells. However, blockade of CXCR3B expression significantly increased the migratory and invasive ability of SK-Hep1 along with increased protein expression of slug, vimentin, and N-cadherin. CXCR3B blockade reduced the cytotoxicity of NK-92 against SK-Hep1 and inhibited the expression of activating receptors, NKp30⁺, NKG2D⁺, and NKG2C⁺ in NK-92 cells.</p><p><strong>Conclusion: </strong>CXCR3B may play a positive role in suppressing HCC by attenuating natural killer cell cytotoxicity against HCC.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5293-5301"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of ERK1/2 Inhibitors on the Growth of Acute Leukemia Cells.","authors":"Mai Itoh, Shuji Tohda","doi":"10.21873/anticanres.17354","DOIUrl":"https://doi.org/10.21873/anticanres.17354","url":null,"abstract":"<p><strong>Background/aim: </strong>Extracellular signal-regulated kinases (ERK)1/2 are important regulatory proteins that control cell proliferation and survival, playing a significant role in cancer progression, metastasis, and chemoresistance. This study investigated the effects of ERK1/2 inhibitors on the in vitro growth of acute leukemia cell lines.</p><p><strong>Materials and methods: </strong>Three ERK1/2 inhibitors were used: SCH772984, temuterkib (LY3214996), and ulixertinib (BVD-523). Four acute myeloid leukemia cell lines (OCI/AML3, HL-60, THP-1, and U-937) and two T-lymphoblastic leukemia cell lines (Jurakt and KOPT-K1) were treated with these inhibitors. Cell growth was assessed using a colorimetric assay, and cell-cycle progression and apoptosis were analyzed using flow cytometry. The expression of intracellular signaling proteins was evaluated via immunoblotting. The effects of small interfering RNA (siRNA)-mediated ERK1/2 knockdown were also evaluated.</p><p><strong>Results: </strong>The inhibitors suppressed the growth of three leukemia cell lines (OCI/AML3, HL-60, and THP-1) harboring neuroblastoma rat sarcoma virus (NRAS) mutations. Growth suppression occurred through G0/G1 arrest in all three cell lines and through apoptosis in OCI/AML3 cells. Immunoblotting demonstrated that these inhibitors suppressed the expression of MYC proto-oncogene, bHLH transcription factor (MYC), in the three cell lines. The additional molecular mechanisms of growth suppression varied depending on the specific inhibitor and cell line. The inhibitors had milder suppressive effects on normal lymphocytes compared to the leukemia cell lines.</p><p><strong>Conclusion: </strong>ERK1/2 inhibitors may serve as novel molecular-targeted drugs for treating leukemia with NRAS mutations.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5263-5270"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resveratrol Can Differentiate Human Melanoma Stem-like Cells from Spheroids Treated With All-trans Retinoic Acid.","authors":"Mina Kanai, Akiho Shinagawa, Masako Ota, Nantiga Virgona, Tomohiro Yano","doi":"10.21873/anticanres.17356","DOIUrl":"https://doi.org/10.21873/anticanres.17356","url":null,"abstract":"<p><strong>Background/aim: </strong>Stem-like cancer cells are believed to be the leading cause of therapy resistance in malignant melanoma (MM). All-trans retinoic acid (ATRA) differentiation therapy is considered a promising approach to eradicate stem-like cancer cells, but some melanoma cells are resistant to ATRA. This study aimed to examine whether resveratrol (RS), a natural polyphenol compound, could improve the response of MM stem-like cells to ATRA and explore the possible underlying mechanisms.</p><p><strong>Materials and methods: </strong>MM stem-like cells were established from a spheroid model of A375 human MM cell line. The response to RES alone and in combination with ATRA, was examined through analysis of cancer stemness, cell viability, and protein expression.</p><p><strong>Results: </strong>The stem-like cells showed resistance to the anticancer drug docetaxel; however, the combination of RES and ATRA augmented the effects of docetaxel. Accordingly, these combinatorial effects were associated with significant inhibition of the expression levels of stemness markers CD133, OCT4, CD271, and ABCG2. The tested combinations also led to a significant increase in melanocyte differentiation marker SOX9, while efficiently suppressing the dedifferentiation marker SOX10. Notably, RES alone effectively up-regulated retinoic acid receptor beta (RARβ) expression and down-regulated crucial mediators like DNMT1, polycomb-group proteins EZH2, and BMI-1, which mechanistically explain how RES enhanced the differentiation-inducing effects of ATRA.</p><p><strong>Conclusion: </strong>The resistance of MM stem-like cells to ATRA can be attenuated by RES and combined applications of ATRA and RES provide a promising strategy for MM treatment.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5283-5292"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Therapy for Postoperative Recurrence: Does Salvage Radiation Work for Locoregional Recurrence?","authors":"Yuri Taniguchi, Takao Shigenobu, Akiko Hayashi, Ayumi Hirahara, Kota Ito, Hiroyuki Shinohara, Aya Shiba, Yuko Higashi, Yuya Tabuchi, Takahiro Suzuki, Masaharu Aga, Yusuke Hamakawa, Kazuhito Miyazaki, Mizuki Sato, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Tsuneo Shimokawa, Kazumasa Odagiri, Akira Yoshizu, Hiroaki Okamoto","doi":"10.21873/anticanres.17380","DOIUrl":"https://doi.org/10.21873/anticanres.17380","url":null,"abstract":"<p><strong>Background/aim: </strong>Survival outcomes in patients with successfully resected non-small-cell lung cancer (NSCLC) are not well understood. Furthermore, the best treatment strategy for postoperative locoregional recurrence has not been established.</p><p><strong>Patients and methods: </strong>Patients who underwent R0 resection of NSCLC between 2013 and 2022 were retrospectively reviewed. The survival after recurrence was analyzed by categorizing patients into locoregional and distant recurrence groups. Moreover, the efficacy of salvage local therapy including radiotherapy (RT) and concurrent chemoradiotherapy (cCRT) was evaluated in terms of progression-free-survival (PFS), overall survival (OS), and safety.</p><p><strong>Results: </strong>Of the 694 patients who underwent R0 surgery, 150 were diagnosed with post-operative recurrence consisting of 54 cases of locoregional and 96 of distant recurrence. The median OS was 55.9 and 22.3 months in the locoregional and distant recurrence groups, respectively [hazard ratio (HR)=0.52; 95% confidence interval (CI)=0.32-0.84; p<0.001]. In the multivariate analysis, distant recurrence, negative oncogenic driver-mutation, and male sex were identified as independent predictors of a poor prognosis. Of the 54 patients with locoregional recurrence, local therapy was administered to 48 comprising 30 cases of cCRT and 18 of RT alone. The median PFS and OS were 13.3 and 60.4 months, respectively. Regarding adverse events, two cases (4.2%) of grade ≥3 radiation pneumonitis occurred.</p><p><strong>Conclusion: </strong>The OS of patients with locoregional recurrence of NSCLC was significantly better than that of patients with distant recurrence. Salvage local therapy, including cCRT and RT, may be an effective option for the treatment of locoregional recurrence due to its superior PFS, OS, and tolerability.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5541-5549"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Innovative Inflammation-nutrition Biomarker Score in Patients With Colorectal Cancer.","authors":"Masatsune Shibutani, Shinichiro Kashiwagi, Hideki Tanda, Yuki Seki, Koji Takada, Hiroaki Kasashima, Tatsunari Fukuoka, Kiyoshi Maeda","doi":"10.21873/anticanres.17382","DOIUrl":"https://doi.org/10.21873/anticanres.17382","url":null,"abstract":"<p><strong>Background/aim: </strong>A new index, inflammation-nutrition biomarker score (INS), based on host factors, including lymphocyte to C-reactive protein ratio, C-reactive protein to albumin ratio, advanced lung cancer inflammation index, and nutritional risk index, correlated with post-operative survival time independent of the tumor, node, metastasis (TNM) stage, in a cohort of patients with various types of malignancies. Therefore, this study aimed to evaluate the prognostic value of INS in patients with colorectal cancer who underwent curative resection.</p><p><strong>Patients and methods: </strong>We retrospectively evaluated 476 consecutive patients who underwent curative surgery for stage I-III colorectal cancer.</p><p><strong>Results: </strong>Based on the INS definition, 240, 132, 57, 23, and 24 patients had a score of 0, 1, 2, 3, and 4, respectively. Patients with INS of 0 and 1 were classified into the low-INS group, and those with INS of 2, 3, and 4 were classified into the high-INS group. The relapse-free and overall survival rates were significantly worse in the high-INS group than in the low-INS group. Furthermore, multivariate analysis of the prognostic factors indicated that INS is an independent prognostic factor for poor relapse-free and overall survival.</p><p><strong>Conclusion: </strong>The combined evaluation of INS and TNM stages may allow for more accurate prognostication.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5559-5567"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Radiation Dose on the Survival of Patients With Non-small Cell Lung Cancer Treated With Palliative Intent: Results of a Multicenter Prospective Study.","authors":"Veronica Cañón, Jose Luis López-Guerra, Ander Arteagoitia, Olga Del Hoyo, Fernan Suarez, David Büchser, Alfonso Gómez-Iturriaga, Arturo Navarro-Martin, Roberto Ortiz DE Zarate, Jose Fernando Pérez Azorín, Dirk Rades, Jon Cacicedo","doi":"10.21873/anticanres.17373","DOIUrl":"10.21873/anticanres.17373","url":null,"abstract":"<p><strong>Background/aim: </strong>Many patients with non-small cell lung cancer (NSCLC) receive palliative radiotherapy (RT). Several factors were analyzed to aid in prescribing an optimal treatment for these patients.</p><p><strong>Patients and methods: </strong>This prospective observational multicenter study investigated several potential factors for associations with overall survival (OS) in 61 patients with NSCLC receiving palliative RT with or without chemotherapy (CT). Investigated factors included age, sex, performance status, history of smoking or alcohol, hemoglobin, co-morbidities, different clinical symptoms, and quality-of-life aspects.</p><p><strong>Results: </strong>Median OS was 10.8 months, and OS rates at 6, 12, and 24 months were 58.5%, 42.5%, and 28.4%, respectively. On multivariate analysis, RT alone (without CT), RT doses ≤30 Gy, advanced tumor stage (stage IV), and poor emotional functioning at diagnosis were associated with significantly worse OS.</p><p><strong>Conclusion: </strong>Patients with NSCLC assigned to palliative RT may benefit from RT doses >30 Gy and additional CT. Sequential CT appears preferable, since concurrent CT increases esophageal toxicity.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5477-5484"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Surgical Decompression With Subsequent Selumetinib Treatment Leads to Drastic Clinical Improvement in a Patient With a Large Spinal Plexiform Neurofibroma.","authors":"Tabea I Hartung, Lan Kluwe, Florian Brembach, Lennart Well, Reinhard E Friedrich, Catena Kresbach, Malte Mohme, Said C Farschtschi","doi":"10.21873/anticanres.17385","DOIUrl":"10.21873/anticanres.17385","url":null,"abstract":"<p><strong>Background/aim: </strong>Plexiform neurofibromas are the hallmark of neurofibromatosis type 1, an autosomal dominantly inherited multisystem disorder. Spinal plexiform neurofibromas can particularly cause severe neurological symptoms. Treatment options are limited due to invasive growth, and targeted therapy with selumetinib is only approved for inoperable tumors in children. The aim of this report was to highlight that selumetinib therapy post-surgery provides an alternative strategy for spinal plexiform neurofibroma, providing both an immediate relief of the symptoms and long-term tumor management.</p><p><strong>Case report: </strong>We describe a patient with neurofibromatosis type 1 and a large spinal plexiform neurofibroma causing severe neurological deficits. A drastic clinical improvement was achieved 6 months after neurosurgical spinal decompression and adjuvant selumetinib therapy.</p><p><strong>Conclusion: </strong>A combination of decompression surgery and selumetinib therapy provides a promising option for the management of spinal plexiform neurofibromas causing severe neurological deficits.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5585-5590"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gallbladder Follicular Lymphoma Mimicking Gallbladder Cancer.","authors":"Takashi Nakagaki, Toshiro Masuda, Yasunori Nagayama, Yoshihiro Komohara, Hiroshi Takeno, Hideaki Miyamoto, Toshihiko Motohara, Yuki Adachi, Eri Oda, Ryuichi Karashima, Takatoshi Ishiko, Toru Beppu","doi":"10.21873/anticanres.17384","DOIUrl":"https://doi.org/10.21873/anticanres.17384","url":null,"abstract":"<p><strong>Background/aim: </strong>Enlarged polypoid gallbladder lesions should first be evaluated to rule out gallbladder cancer. Gallbladder lymphoma rarely develops, and gallbladder follicular lymphoma is seldom observed.</p><p><strong>Case report: </strong>The case of a 70-year-old man with an enlarged polypoid gallbladder lesion and stable-sized multiple enlarged mesenteric lymph nodes is reported. No specific symptoms and obvious abnormalities were observed in laboratory data, such as tumor markers or soluble interleukin-2 receptor levels. The polypoid gallbladder lesion had enlarged from 10 mm to 15 mm in 1 year, had a slightly irregular surface, and showed moderate early enhancement with delayed washout on multiphase contrast-enhanced computed tomography (CT). The apparent diffusion coefficient on diffusion-weighted magnetic resonance imaging was 0.95×10^-3 mm²/s, indicating the high cell density and high water diffusion restriction. Positron-emission tomography/computed tomography revealed no increased fluorodeoxyglucose activity in the gallbladder lesion. Laparoscopic total cholecystectomy and excisional biopsy of the mesenteric lymph nodes were performed. Numerous polypoid lesions were detected in intraoperative contrast-enhanced ultrasonography with a high contrast effect. Gross specimens contained numerous polypoid lesions of various sizes. Immunohistochemical staining identified tumor lymphocytes positive for CD10, CD20, and BCL2 apoptosis regulator (BCL2), and CD23-positive fibroblastic reticulocytes forming a reticular network within the nodules. The gallbladder and mesenteric lymph nodes were finally diagnosed as grade 1 follicular lymphoma. The patient is being closely monitored every 6 months without medication.</p><p><strong>Conclusion: </strong>Gallbladder follicular lymphoma is difficult to diagnose preoperatively, however, extra-regional lymph node swelling and relatively low apparent diffusion coefficients on magnetic resonance imaging can help its diagnosis.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5577-5583"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Warm Ischemia Time on HER2 Expression in Breast Cancer Surgical Specimens.","authors":"Nobuyasu Suganuma, Yuka Matsubara, Akari Takahashi, Takashi Yamanaka, Toshinari Yamashita, Emi Yoshioka, Kae Kawachi, Tomonori Yokose, Hiroto Narimatsu, Daisuke Hoshino, Yohei Miyagi, Aya Saito","doi":"10.21873/anticanres.17350","DOIUrl":"https://doi.org/10.21873/anticanres.17350","url":null,"abstract":"<p><strong>Background/aim: </strong>Tissue sample quality control has become increasingly crucial as these samples are integral to basic research and clinical practice, particularly in immunohistochemistry and gene panel testing. Standard PREanalytical Code (SPREC) was developed to standardize pre-analytical processes, including warm ischemia time (WIT), cold ischemia time (CIT), and fixation time (FT), which can influence the surgical specimen quality. This study investigated the impact of WIT, CIT, and FT on estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) expression in breast cancer (BC) surgical specimens.</p><p><strong>Patients and methods: </strong>We enrolled 277 patients with first-time BC who underwent surgery at Kanagawa Cancer Center between May 2018 and April 2019. WIT, CIT, and FT were recorded using SPREC ver. 3.0, and their effects on ER, PgR, and HER2 expression were analyzed using immunohistochemistry. Surgical specimens were compared with preoperative needle biopsy samples from the same tumors to control for WIT, CIT, and FT variability.</p><p><strong>Results: </strong>The median WIT, CIT, and FT were 23 min, 37 min, and 43 h, respectively. Compliance with the American Society of Clinical Oncology/College of American Pathologists guidelines was 91.7% for CIT and 94.9% for FT. ER and PgR expression in surgical specimens decreased with prolonged CIT and FT, but differences were non-significant. However, HER2 expression increased significantly when WIT exceeded 30 min.</p><p><strong>Conclusion: </strong>WIT could significantly influence HER2 expression in BC surgical specimens, highlighting the need for meticulous WIT control during BC surgery to ensure accurate HER2 assessment, which is critical for guiding therapeutic decisions.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5225-5230"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Methylation of Tumor-suppressive miRNAs and <i>KRAS/TP53</i> Mutations in Pancreatic Juice.","authors":"Koushiro Ohtsubo, Kunio Miyake, Shigeki Sato, Hiroyuki Sakaguchi, Koji Fukuda, Hiroshi Kotani, Akihiro Nishiyama, Shigeki Nanjo, Kaname Yamashita, Shinji Takeuchi, Seiji Yano, Sawako Kuruma, Jun Nakahodo, Masataka Kikuyama, Hiroaki Taniguchi","doi":"10.21873/anticanres.17353","DOIUrl":"https://doi.org/10.21873/anticanres.17353","url":null,"abstract":"<p><strong>Background/aim: </strong>We previously reported the usefulness of detecting aberrant methylation in tumor suppressive microRNAs (miRNAs) in bile and plasma to discriminate pancreaticobiliary cancers from benign pancreaticobiliary diseases. This study analyzed the methylation of miRNAs in pancreatic juice to identify those specific to pancreatic cancer (PC).</p><p><strong>Patients and methods: </strong>Pancreatic juice was collected from 20 patients with PC, including eight with intraductal papillary mucinous carcinoma (IPMC), two with low grade-pancreatic intraepithelial neoplasia (LG-PanIN), 32 with LG-intraductal papillary mucinous neoplasm (IPMN), and seven with benign pancreatic lesions. Polymerase chain reaction amplification and sequencing were performed for three tumor suppressive miRNAs (miR-200a, 200b, and 1247), and their methylation rates were determined. Additionally, KRAS and TP53 mutations were analyzed.</p><p><strong>Results: </strong>The methylation rate of miR-1247 was significantly higher in patients with PC than in those with LG-PanIN/IPMN. Furthermore, it was significantly higher in patients with IPMC than in those with LG-IPMN. KRAS and TP53 mutations were detected in seven (70%) and one (10%) of the patients with PC, respectively.</p><p><strong>Conclusion: </strong>Analyzing the methylation of miR-1247 in addition to KRAS and TP53 mutations in pancreatic juice may be useful to distinguish PC from PanIN/IPMN.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5253-5261"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}